1. How do glucagon-like peptide-1 receptor agonists work to control blood sugar levels in patients with diabetes?
A. By increasing levels of thyroid hormone
B. By increasing appetite
C. By mimicking incretin hormone activity
D. By causing excess sugar in the body to be excreted by the kidneys
2. Which non-insulin injectable is dosed once weekly?
A. Liraglutide
B. Pramlintide
C. Dulaglutide
D. Regular-release exenatide
3. Which of the following adverse effects is common to all non-insulin injectable medications for diabetes?
A. Upper respiratory tract infections
B. Pancreatitis
C. Weight gain
D. Nausea
4. How do incretins help regulate blood glucose?
A. They are released from the gastrointestinal tract and work to slow gastric emptying, promote insulin release, and suppress glucagon release
B. They are released from the pancreas and they work to slow gastric emptying and suppress glucagon release
C. They are released from the gastrointestinal tract and they work to suppress insulin release and promote glucagon release
D. They are released from the pancreas and they work to suppress insulin release and promote glucagon release
5. The GLP-1 RAs demonstrate a robust A1C reduction of about what percentage?
A. < 1%
B. 1% to 1.5%
C. 1% to 2.0 %
D. > 2.0%
6. The most common side effects associated with GLP-1 RAs are:
A. constipation and euphoria
B. nausea, diarrhea, and headache
C. nausea, constipation and rash
D. headache and rash
7. Which non-insulin injectable is indicated for both type 1 and type 2 diabetes?
A. Exenetide
B. Albiglutide
C. Liraglutide
D. Pramlinitide
8. Exenatide is available as:
A. Regular only
B. Extended-release only
C. Regular and extended-release
D. Exenatide is not currently on the market
9. Liraglutide has been shown to reduce A1C by about what percentage?
A. >1.5%
B. 3%
C. 2%
D. 1%
10. How can non-insulin injectable agents such as exenatide cause potential drug interactions?
A. By slowing gastric emptying
B. By causing injection site reactions
C. By increasing blood sugar levels
D. By decreasing thyroid hormone secretion
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20